author-photo

Mads Emil Bjørn

Roskilde University

11

Papers

302

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

2018 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (28)
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms

2015 Mediators of Inflammation
- Mads Emil Bjørn
- Hans Carl Hasselbalch
Show All
- Source
- Cite
- Save
Citations (35)
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

2015 Mediators of Inflammation
- Hans Carl Hasselbalch
- Mads Emil Bjørn
Show All
- Source
- Cite
- Save
Citations (101)
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

2015 The New England Journal of Medicine
- Hans Carl Hasselbalch
- Mads Emil Bjørn
Show All
- Source
- Cite
- Save
Citations (37)
Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].

2015 Leukemia research reports
Show All
- Source
- Cite
- Save
Citations (7)
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms

2015 Clinical Case Reports
- Mads Emil Bjørn
- Hans Carl Hasselbalch
Show All
- Source
- Cite
- Save
Citations (12)
Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

2014 Leukemia research reports
Show All
- Source
- Cite
- Save
Citations (27)